Search

Displaying results 4951 - 4960 of 10000 in total
  1. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    Somapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency. … [A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666]

  2. Drug

    Amediplase

    go.drugbank.com/drugs/DB06679
    Experimental

    Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase.

  3. Drug

    Zuretinol acetate

    go.drugbank.com/drugs/DB12112
    Investigational

    Zuretinol acetate has been used in trials studying the treatment of Impaired Dark Adaptation, RP (Retinitis Pigmentosa), Retinitis Pigmentosa (RP), and LCA (Leber Congenital Amaurosis).

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    TRO40303

    go.drugbank.com/drugs/DB16031
    Investigational

    TRO40303 is under investigation in clinical trial NCT01374321 (Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute

  5. Drug

    Nitrilotriacetic acid

    go.drugbank.com/drugs/DB03040
    Experimental

    Nitrilotriacetic acid is a derivative of acetic acid, N(CH2COOH)3. It is a complexing (sequestering) agent that forms stable complexes with Zn2+. (From Miall's Dictionary of Chemistry, 5th ed.)

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary … Despite the clear association of Aβ aggregation with AD, treatments aimed at preventing Aβ aggregation or removing pre-existing Aβ plaques have shown little to no clinical benefit thus far and remain controversial

  7. Drug

    G4544

    go.drugbank.com/drugs/DB05244
    Experimental

    G4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite™ (gallium nitrate injection).

  8. Drug

    YKP-1358

    go.drugbank.com/drugs/DB06109
    Experimental

    In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects. … YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.

  9. Drug

    SP1049C

    go.drugbank.com/drugs/DB04978
    Experimental

    [A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. … Preliminary data, in its first clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of the esophagus.

    Synonyms: doxorubicin with pluronics F-127 and L-61, Doxorubicin HCl with pluronic L-61 and pluronic F-127Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Licofelone

    go.drugbank.com/drugs/DB04725
    Experimental

    Although phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given. … It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis.